68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

Tumor, Solid Clinical Trial

Official title:

Clinical Applications of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracer 68Ga-DOTA-F2 PET/CT Imaging for Malignant Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05637034
• Other study ID #: I-22PJ292
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2022
• Est. completion date: September 15, 2023

Study information

• Verified date: November 2022
• Source: Peking Union Medical College Hospital
• Contact: Peipei Wang, MD
• Phone: 18511395988
• Email: wpp199411[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.

Description:

Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs; e.g., FAPI-04 and FAPI-46), which have shown promising results in the diagnosis of cancer and various other diseases in recent years, have become the focus of much productive research. Despite this, one major issue is that these FAPI molecules have a relatively short tumor retention time, which may limit their use in targeted radionuclide therapy applications. As a result, 68Ga-DOTA-F2, a novel dimeric FAPI molecule, was developed to increase tracer uptake and retention in tumors for potential therapeutic or theranostic applications. In preclinical study, 68Ga-DOTA-F2 has shown better tumor uptake and longer tumor retention time than 68Ga-FAPI in mouse tumor models. Our study will assess image quality and evaluate the diagnostic performance of 68Ga-DOTA-F2. Patients with histologically confirmed malignant tumors will be prospectively recruited in this study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 15, 2023
• Est. primary completion date: September 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Subject is aged 18 years or older

2. Signed Informed Consent

3. Subject is pathologically confirmed with a malignant tumor

4. Subject is judged to be in good general condition by the investigator based on medical history, physical examination including vital signs and clinical laboratory tests, besides the diagnosis of malignant tumor

5. Female subjects should be post-menopausal or surgically sterile or using effective contraceptive with the negative pregnancy test

Exclusion Criteria:

1. Subject has a previous or ongoing recurrent or chronic disease, other than malignant tumor, at high risk to interfere with the evaluation of the trial according to the judgment of the investigator

2. Subject with non-malignant lesions;

3. Subject with the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

4. Subject is potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding

Related Conditions & MeSH terms

• Tumor, Solid

Intervention

Diagnostic Test:
• 68Ga-DOTA-F2 PET/CT and 18F-FDG
Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.

Locations

Country	Name	City	State
China	Peking union medical college hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardized uptake value (SUV)	Standardized uptake value (SUV) of 68Ga-DOTA-F2 and 18F-FDG for each primary tumor of subject or suspected lymph metastasis	through study completion, an average of 1 year
Primary	Lession detection ability	Lession number detected by 68Ga-DOTA-F2 and 18F-FDG PET/CT	through study completion, an average of 1 year
Secondary	Sensitivity	The sensitivity of 68Ga-DOTA-F2 PET/CT and 18F-FDG PET/CT	through study completion, an average of 1 year
Secondary	Specificity	The specificity of 68Ga-DOTA-F2 PET/CT and 18F-FDG PET/CT	through study completion, an average of 1 year
Secondary	Radiation Dosimetry	Mean absorbed radiation doses were estimated using the source and target organ framework. Five patients with different cancers underwent serial 68Ga-DOTA-F2 PET/CT scans at five-time points following radiotracer injection: 5 minutes, 15 minutes, 30 minutes, 1 hour, and 3 hours. The source organs consisted of the kidneys, bladder, liver, heart, spleen, bone marrow, uterus, and body remainder. OLINDA/EXM software was used to fit and integrate the kinetic organ activity data to yield total body and organ time-integrated activity coefficients/residence times and finally organ absorbed doses.	30 days